Kaletra and Paclitaxel Concentrate Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Talk to your doctor before using PACLitaxel together with ritonavir. Combining these medications may significantly increase the blood levels of PACLitaxel. This may increase the risk of side effects such as nausea, vomiting, diarrhea, mouth sores, nerve pain, numbness, tingling, vision abnormalities, muscle pain or weakness, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration with certain antiretroviral agents such as protease inhibitors and delavirdine may increase the plasma concentrations and pharmacologic effects of paclitaxel. The proposed mechanism is inhibition of the CYP450 3A4-mediated metabolism of paclitaxel. There have been case reports of life-threatening toxicity and death in patients treated with paclitaxel 100 mg/m2 (a dosage previously found to be safe and effective for AIDS-related Kaposi's sarcoma) who were also receiving highly active antiretroviral therapy (HAART) that included ritonavir, ritonavir/lopinavir, indinavir, saquinavir, and/or delavirdine, all of which are known potent inhibitors of the CYP450 3A4 isoenzyme. Symptoms of toxicity included myalgias, arthralgias, mucositis, febrile neutropenia, leucopenia, thrombocytopenia, infection, alopecia, and ECG abnormalities. A dosage reduction to 60 mg/m2 and concomitant administration with granulocyte colony-stimulating factor (G-CSF) were subsequently required in the patients who recovered.

MANAGEMENT: Caution is advised if paclitaxel is required in patients receiving protease inhibitors and/or delavirdine. A lower initial dosage of paclitaxel may be appropriate. Patients should be closely monitored for the development of dose-related paclitaxel toxicity such as myelosuppression, stomatitis, arthralgia, myalgia, visual disturbances and peripheral neuropathy, and the paclitaxel dosage further adjusted as necessary.

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?

Paclitaxel Concentrate Injection

Generic Name: paclitaxel

Brand name: Onxol, Taxol

Synonyms: Paclitaxel, PACLitaxel (Conventional)

What is Paclitaxel Concentrate Injection?